NICE updates methods in preparation for "widespread" use of biosimilars
This article was originally published in Scrip
Executive Summary
The National Institute for Health and Care Excellence (NICE) has reviewed and updated its methods for providing guidance and advice on biosimilars in preparation for an expected increase in the number of such products coming onto the market. Among other things it says biosimilars could be subject either to a technology appraisal (guidance) or to a less prescriptive "evidence summary".